Diabète de type 2 et médicaments anti-inflammatoires: Nouvelles perspectives thérapeutiques?

Translated title of the contribution: Type 2 diabetes and anti-inflammatory agents: New therapeutic prospects?

N. Esser, N. Paquot, A. J. Scheen

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

It is now well accepted that a chronic, low-grade inflammation is observed in abdominal obesity, insulin resistance and type 2 diabetes mellitus, and that pro-inflammatory cytokines and oxidative stress play a role in the pathogenesis of type 2 diabetes. These new findings raise the question of whether antiinflammatory strategies may have a place in the prevention and treatment of type 2 diabetes. This review article describes the results obtained in studies on patients with metabolic syndrome or type 2 diabetes aiming to test the metabolic effect of anti-inflammatory (salicylates, antagonists of interleukine-1, antagonists of tumor necrosis factor-alpha) and anti-oxydants (succinobucol) drugs.

Translated title of the contributionType 2 diabetes and anti-inflammatory agents: New therapeutic prospects?
Original languageFrench
Pages (from-to)1614-1620
Number of pages7
JournalRevue Medicale Suisse
Volume7
Issue number306
StatePublished - 30 Aug 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'Type 2 diabetes and anti-inflammatory agents: New therapeutic prospects?'. Together they form a unique fingerprint.

Cite this